Hematology (Amsterdam, Netherlands) · 2025
First case report: near early T-cell precursor acute lymphoblastic leukemia with plasmacytoid dendritic cell proliferation effectively treated with Venetoclax plus HAG regimen.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Jiongping, Li Dan, Luo Hongqiang, Chen Zhe, Feng Yi, Liu Fang, Wang Liping, Huang Xin, Feng Weiying
Аннотация
BACKGROUND: Near early T-cell precursor acute lymphoblastic leukemia represents a distinct subtype of T-cell acute lymphoblastic leukemia characterized by specific immunophenotypic and molecular biological characteristics. Currently, no standardized treatment protocol exists.
METHODS: This study presents a case of near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) characterized by plasmacytoid dendritic cell proliferation, which manifested clinically through pancytopenia and generalized multiple rashes.
RESULTS: The patient underwent successful treatment with chemotherapy consisting of Venetoclax combined with HAG regimen administered for one cycle.
DISCUSSION: This case report provides preliminary evidence suggesting that the combination of Venetoclax with HAG (homoharringtonine, cytarabine, and granulocyte colony-stimulating factor) regimen may constitute an effective and tolerable therapeutic approach for patients with near ETP-ALL. However, these initial observations necessitate further validation through comprehensive clinical studies with larger sample sizes to definitively establish the treatment's efficacy and safety profile.
METHODS: This study presents a case of near early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) characterized by plasmacytoid dendritic cell proliferation, which manifested clinically through pancytopenia and generalized multiple rashes.
RESULTS: The patient underwent successful treatment with chemotherapy consisting of Venetoclax combined with HAG regimen administered for one cycle.
DISCUSSION: This case report provides preliminary evidence suggesting that the combination of Venetoclax with HAG (homoharringtonine, cytarabine, and granulocyte colony-stimulating factor) regimen may constitute an effective and tolerable therapeutic approach for patients with near ETP-ALL. However, these initial observations necessitate further validation through comprehensive clinical studies with larger sample sizes to definitively establish the treatment's efficacy and safety profile.